
|Videos|December 23, 2020
New Mechanism for Treatment of Schizophrenia
Author(s)Stephen Brannan, MD
Hear details from the phase II trial of xanomeline-trospium and how it assists in the treatment of acute schizophrenia.
Advertisement
Stephen Brannan, MD, Chief Medical Officer of Karuna Therapeutics, talks more on their additional data presentation from the ACNP.
To get a closer look at the Phase 2 EMERGENT-1 poster that was presented at ACNP, see
Dr Brannan is chief medical officer at Karuna Therapeutics and a neuroscience drug development expert.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
Zuranolone in the Room: Closing the Gap in Postpartum Depression Care
2
Classic Drug, New Target: Lithium as Disease-Modifying in Alzheimer Dementia
3
Vol 43, Issue 7 - Interactive
4
The Psychiatric Impact of Cannabis Policy: More Than a Legal Framework
5










